Zacks Research Issues Positive Forecast for AbbVie Earnings

AbbVie Inc. (NYSE:ABBV - Free Report) - Analysts at Zacks Research upped their FY2025 EPS estimates for shares of AbbVie in a research note issued to investors on Tuesday, February 18th. Zacks Research analyst S. Ganoria now anticipates that the company will post earnings per share of $12.14 for the year, up from their prior forecast of $11.94. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie's Q4 2025 earnings at $3.39 EPS, Q4 2026 earnings at $3.77 EPS and FY2026 earnings at $13.57 EPS.

Several other research analysts have also recently issued reports on ABBV. Daiwa Capital Markets cut shares of AbbVie from an "outperform" rating to a "neutral" rating and set a $180.00 target price for the company. in a report on Thursday, December 5th. Leerink Partners raised shares of AbbVie from a "market perform" rating to an "outperform" rating and set a $206.00 target price for the company in a report on Friday, November 22nd. Argus raised shares of AbbVie from a "hold" rating to a "buy" rating in a report on Monday, November 4th. UBS Group boosted their price objective on shares of AbbVie from $181.00 to $190.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Finally, Wells Fargo & Company boosted their price objective on shares of AbbVie from $195.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average price target of $208.35.

AbbVie Stock Up 0.6 %

NYSE ABBV traded up $1.15 during trading hours on Friday, reaching $202.03. 5,879,957 shares of the company's stock traded hands, compared to its average volume of 5,370,269. AbbVie has a 52-week low of $153.58 and a 52-week high of $207.32. The firm has a market cap of $356.64 billion, a PE ratio of 84.18, a PEG ratio of 1.61 and a beta of 0.58. The firm has a 50-day simple moving average of $181.25 and a 200 day simple moving average of $186.41. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.54.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same quarter in the previous year, the firm earned $2.79 EPS.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.25%. AbbVie's payout ratio is currently 273.33%.

Insiders Place Their Bets

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the company's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.25% of the company's stock.

Hedge Funds Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. American Trust boosted its position in shares of AbbVie by 185.6% during the fourth quarter. American Trust now owns 19,111 shares of the company's stock worth $3,396,000 after acquiring an additional 12,420 shares during the last quarter. Ascent Group LLC boosted its position in shares of AbbVie by 5.7% during the fourth quarter. Ascent Group LLC now owns 25,936 shares of the company's stock worth $4,609,000 after acquiring an additional 1,389 shares during the last quarter. Putney Financial Group LLC bought a new position in shares of AbbVie during the fourth quarter worth $784,000. PVG Asset Management Corp bought a new position in shares of AbbVie during the fourth quarter worth $425,000. Finally, Vermillion Wealth Management Inc. purchased a new stake in AbbVie during the fourth quarter valued at $122,000. Institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.